Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of $0.03, $0.05 worse than the analyst estimate of $0.08. Revenue for the quarter came in at $46.06 million versus the consensus estimate of $62 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.